In our previous article, we shared the story of Branden, a child living with Spinal Muscular Atrophy (SMA) Type 1, whose journey reflects the transformative impact of timely access to treatment. Once facing the bleakest of prognoses, Branden now paints, creates, and dreams of a future, because science offered a solution, and access made it possible
The Power of Progress in SMA Treatment
Branden’s journey demonstrates that spinal muscular atrophy (SMA) is no longer untreatable. Thanks to medical innovation, he paints, creates, and dreams of the future. Yet, thousands of children worldwide still lack access to these life-changing medicines. While science has delivered solutions, equitable distribution remains a challenge - one that calls for government action and global collaboration, not division.
Balancing Innovation and Accessibility
Pharmaceutical companies play a vital role in advancing SMA medicines, investing heavily in research and development. However, the high costs of these medicines create barriers for families in Malaysia and beyond. Many face impossible choices: mortgaging homes, taking loans, or watching their loved one’s decline. Newer medicines, such as single-dose gene treatments, offer hope but also highlight the need for sustainable pricing models that align with diverse economic realities.
The divide continues to grow, as those in countries with reimbursed access not only have their lives saved and are thriving, but also the benefit of choice - including, for some, access to dual therapies. This disparity highlights the urgent need for policies and partnerships that ensure every child, regardless of geography or income, has the same chance at life and potential.
Global Lessons in Equity
An Indian pharmaceutical company’s affordable generic version of an SMA medice demonstrates how intellectual property rights can be balanced with public health priorities. Similarly, Argentina and Russia have developed biosimilars for another SMA medicine, while China has introduced several follow-on gene therapies. These developments, alongside ongoing legal debates, underscore the importance of constructive dialogue - not confrontation - in bridging the gap between innovation and accessibility.
China has led the way with bulk purchasing and tiered pricing models for SMA medicines, negotiating directly with manufacturers to reflect national income levels and sharply reduce SMA costs while maintaining manufacturer engagement.
Several European health systems use outcomes-based managed-entry agreements, tying reimbursement to real-world patient outcomes. These schemes cap payer budgets and incentivize effective care delivery, enabling earlier access under shared-risk frameworks.
Singapore’s Medication Assistance Fund (MAF) subsidizes an SMA medicine based on a means test with patients receiving up to 75% off their medication costs. For those still unable to afford co-payments after
MAF subsidies, MediFund offers additional financial assistance through a holistic assessment that includes household structure and social circumstances. Bangladesh’s progress towards a fund dedicated for SMA, even with limited resources, inspires hope that
Malaysia can certainly adapt similar strategies.
A Call for Partnership
To pharmaceutical partners, we recognize the value of innovation and urge collaborative pricing models that reflect Malaysia’s economic context. By aligning profit with purpose with pricing compatible with Malaysia, we can ensure life-saving treatments reach those who need them most.
To policymakers and doctors, you have laid critical groundwork for advancing SMA care: doctors have refined treatment protocols, public and private hospitals are safely administering SMA medicines, and diverse political and public support reflects growing recognition of the urgency.
A Shared Commitment
Malaysia need not strive for perfection, but it must act with urgency. Doctors are ready. Families are advocating. The world is watching. Let 2025 be the year Malaysia brings together all stakeholders to ensure no child with SMA is left behind. Until then, too many innocent Malaysian children and adults will continue to die.
Together, we can turn scientific breakthroughs into lived realities, proving that equity and compassion can shape a brighter future for all.
Edmund Lim, father of Branden living with SMA Type 1, reminds us that science and equity can change the world, together.
